A hybrid indoloquinolizidine peptide as allosteric modulator of dopamine D1 receptors
- PMID: 20026675
- DOI: 10.1124/jpet.109.158824
A hybrid indoloquinolizidine peptide as allosteric modulator of dopamine D1 receptors
Abstract
The indoloquinolizidine-peptide 28 [(3S,12bR)-N-((S)-1-((S)-1-((S)-2-carbamoylpyrrolidin-1-yl)-3-(4-fluorophenyl)-1-oxopropan-2-ylamino)-4-cyclohexyl-1-oxobutan-2-yl)-1,2,3,4,6,7,12, 12b-octahydroindolo[2,3-a]quinolizine-3-carboxamide], a trans-indoloquinolizidine-peptide hybrid obtained by a combinatorial approach, behaved as an orthosteric ligand of all dopamine D(2)-like receptors (D(2), D(3), and D(4)) and dopamine D(5) receptors, but as a negative allosteric modulator of agonist and antagonist binding to striatal dopamine D(1) receptors. Indoloquinolizidine-peptide 28 induced a concentration-dependent hyperbolic increase in the antagonist apparent equilibrium dissociation constant values and altered the dissociation kinetics of dopamine D(1) receptor antagonists. The negative allosteric modulation was also found when agonist binding to D(1) receptors was assayed. Indoloquinolizidine-peptide 28 was a weak ago-allosteric modulator but markedly led to a decreased potency without decreasing the maximum partial/full agonist-mediated effect on cAMP levels. Compounds able to decrease the potency while preserving the efficacy of D(1) receptor agonists are promising for exploration in psychotic pathologies.
Similar articles
-
Dopamine D1 and D2 agonist effects on prepulse inhibition and locomotion: comparison of Sprague-Dawley rats to Swiss-Webster, 129X1/SvJ, C57BL/6J, and DBA/2J mice.J Pharmacol Exp Ther. 2005 Feb;312(2):733-41. doi: 10.1124/jpet.104.074468. Epub 2004 Oct 19. J Pharmacol Exp Ther. 2005. PMID: 15494551
-
Differential activation of adenylate cyclase and receptor internalization by novel dopamine D1 receptor agonists.Mol Pharmacol. 2005 Oct;68(4):1039-48. doi: 10.1124/mol.105.012153. Epub 2005 Jun 28. Mol Pharmacol. 2005. PMID: 15985612
-
Intracellular Binding Site for a Positive Allosteric Modulator of the Dopamine D1 Receptor.Mol Pharmacol. 2018 Oct;94(4):1232-1245. doi: 10.1124/mol.118.112649. Epub 2018 Aug 15. Mol Pharmacol. 2018. PMID: 30111649
-
Retinal dopamine D1 and D2 receptors: characterization by binding or pharmacological studies and physiological functions.Cell Mol Neurobiol. 1990 Sep;10(3):303-25. doi: 10.1007/BF00711177. Cell Mol Neurobiol. 1990. PMID: 2174740 Free PMC article. Review.
-
The First Negative Allosteric Modulator for Dopamine D2 and D3 Receptors, SB269652 May Lead to a New Generation of Antipsychotic Drugs.Mol Pharmacol. 2017 Jun;91(6):586-594. doi: 10.1124/mol.116.107607. Epub 2017 Mar 6. Mol Pharmacol. 2017. PMID: 28265019 Free PMC article. Review.
Cited by
-
Allosteric Modulators of G Protein-Coupled Dopamine and Serotonin Receptors: A New Class of Atypical Antipsychotics.Pharmaceuticals (Basel). 2020 Nov 14;13(11):388. doi: 10.3390/ph13110388. Pharmaceuticals (Basel). 2020. PMID: 33202534 Free PMC article. Review.
-
Quantifying the inverted U: A meta-analysis of prefrontal dopamine, D1 receptors, and working memory.Behav Neurosci. 2022 Jun;136(3):207-218. doi: 10.1037/bne0000512. Epub 2022 Apr 7. Behav Neurosci. 2022. PMID: 35389678 Free PMC article.
-
New therapeutic strategies targeting D1-type dopamine receptors for neuropsychiatric disease.Front Biol (Beijing). 2015 Jun;10(3):230-238. doi: 10.1007/s11515-015-1360-4. Epub 2015 May 13. Front Biol (Beijing). 2015. PMID: 28280503 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
